Compare · DXCM vs IINN
DXCM vs IINN
Side-by-side comparison of DexCom Inc. (DXCM) and Inspira Technologies Oxy B.H.N. Ltd. (IINN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and IINN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.65B, about 2016.1x IINN ($16.7M).
- DXCM has been more active in the news (9 items in the past 4 weeks vs 8 for IINN).
- DXCM has more recent analyst coverage (25 ratings vs 2 for IINN).
- Company
- DexCom Inc.
- Inspira Technologies Oxy B.H.N. Ltd.
- Price
- -
- -
- Market cap
- $33.65B
- $16.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 9
- 8
- Recent ratings
- 25
- 2
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.
Latest IINN
- SEC Form 424B5 filed by Inspira Technologies Oxy B.H.N. Ltd.
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- QTREX Announces Pricing of a $10 Million Registered Direct Offering of Ordinary Shares
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- QTREX's Patent-Pending Technology Achieves First Direct Conversion of 3D-Printed Insulation into Graphene-Like Carbon to Protect Quantum Processors
- QTREX and U.S. Department of Defense Laboratory Target Q4 2026 to Formalize Joint Quantum Development Program
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.
- SEC Form EFFECT filed by Inspira Technologies Oxy B.H.N. Ltd.
- QTREX Proprietary Quantum Interconnect Platform Exceeds Performance Requirements Established by Strategic Partners
- SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.